US Pharma MarketingThe Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.
As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next
As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: PharmaVoice